Fat specific protein 27 inhibits lipolysis by facilitating the inhibitory effect of Egr1 on transcription of adipose triglyceride lipase.

Running title: FSP27 decrease transcription of ATGL via Egr1

Maneet Singh, Rajween Kaur, Mi-Jeong Lee, R. Taylor Pickering, Vishva Mitra Sharma, Vishwajeet Puri, and Konstantin V. Kandror

Boston University School of Medicine, Boston, MA 02118

# Co-corresponding authors

Addresses for correspondence: V. Puri, Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, 650 Albany Street, Boston MA 02118, Phone 617/638-8192, E-mail vpuri@bu.edu

K. V. Kandror, Boston University School of Medicine, Department of Biochemistry, 72 East Albany Street, Boston, MA 02118, Phone 617/638-5049, Fax 617/638-5339, E-mail kkandror@bu.edu

Capsule

Background: FSP27 is a lipid droplet associated protein.

Results: Expression of FSP27 in human adipocytes reversely correlates with ATGL levels. Mechanistically, FSP27 increases the inhibitory effect of Egr1 on the ATGL promoter.

Conclusions: FSP27 controls lipolysis by regulating ATGL transcription.

Significance: Our study provides a new model of regulation of lipolysis in adipocytes.

Key Words: FSP27, ATGL, Egr1, lipolysis, adipocytes

Lipolysis in fat tissue represents a major source of circulating fatty acids. Previously, we have found that lipolysis in adipocytes is controlled by early growth response transcription factor Egr1 that directly inhibits transcription of adipose triglyceride lipase, ATGL (Chakrabarti et al., Mol. Cell Biol. 2013, 33, 3659-3666). Here we demonstrate that knock down of the lipid droplet protein FSP27 (a.k.a. CIDEC) in human adipocytes increases expression of ATGL at the level of transcription, whereas overexpression of FSP27 has the opposite effect. FSP27 suppresses the activity of the ATGL promoter in vitro, and the proximal Egr1 binding site is responsible for this effect. FSP27 co-immunoprecipitates with Egr1 and increases its association with and inhibition of the ATGL promoter. Knockdown of Egr1 attenuates the inhibitory effect of FSP27. These results provide a new model of transcriptional regulation of ATGL.

Current epidemics of metabolic diseases, such as type 2 diabetes, cardiac dysfunction, hypertension,
hepatic steatosis, etc., is largely caused by widespread obesity. Although obesity can affect human health via several different mechanisms (1), the best-established connection between obesity and metabolic disease is abnormal levels of circulating fatty acids (FA). FA play important physiological roles in energy production and the synthesis of most lipids; nonetheless, their oversupply is highly detrimental as it leads to insulin resistance, oxidative stress, and other pathophysiological effects via mechanisms that are currently under intense investigation (1-5).

Normally, dietary FA are partitioned into adipose tissue, converted into triglycerides (TG), and stored in lipid droplets (LDs) that represent dynamic intracellular organelles consisting of a core of TG and cholesterol esters, surrounded by a monolayer of phospholipids. Several proteins are associated with this monolayer, notably the PAT-family proteins, PLIN 1-5, (6,7) and Fat Specific Protein 27 (FSP27, also known as CIDEC) (8-10). The latter protein plays an essential role in the regulation of LD morphology. Depletion of FSP27 in adipocytes leads to fragmentation of LDs (11,12), while over-expression of FSP27 increases the size of LDs while decreasing their number (8,9,12) by promoting LD fusion (13) and exchanging lipids from one droplet to another (14).

It has also been demonstrated by us and others that FSP27 has anti-lipolytic activity (8,9,12,15-18). Lipolysis in adipose tissue is the major source of circulating FA (19-24). Correspondingly, unrestricted lipolysis in adipose tissue represents a serious metabolic defect and a causative factor of insulin resistance, diabetes mellitus, and other metabolic diseases (3,25-27). As the mechanism of the anti-lipolytic activity of FSP27 is not completely clear, we decided to focus on this problem.

Our recent study showed that FSP27 directly interacts with ATGL and regulates its lipase activity (18). Another study predicted that FSP27-mediated fusion of LDs might limit the access of intracellular lipases to the LD surface due to decreased surface area of larger LDs (17). As ATGL represents a major lipolytic enzyme (28), reducing its contact with LDs may suppress lipolysis.

Here, we report another mechanism of the anti-lipolytic action of FSP27 in human adipocytes. We have found that FSP27 inhibits expression of ATGL at the level of transcription by stimulating the effect of its transcriptional repressor Egr1.

**EXPERIMENTAL PROCEDURES**

**Cell Culture** - Human pre-adipocytes were procured from the Boston Nutrition Obesity Research Center adipocyte core. Cells were seeded at a density of 5,000 cells/ml/well in a 12-well plate, in Growth Medium which was made using 13.5 g of α-MEM powder (Gibco) with 10% FBS (Gibco), 100 units/ml of penicillin and streptomycin (Gibco) and 25mM Sodium Bicarbonate (Fisher Scientific) reconstituted in double-distilled water (ddH₂O) to 1 liter, pH 7.2-7.3. This growth medium was changed every 2 days, until cells reached 90% confluence. In order to allow the cells to differentiate, the GM was then replaced by Complete Differentiation Medium, which consisted of: 13.5 g of Dulbecco’s Modified Eagle’s medium powder (DMEM)/F12 (Gibco), 100 units/ml of penicillin and streptomycin (Gibco), 15mM Hepes (Sigma), 25mM Sodium Bicarbonate (Fisher Scientific), 33µM Biotin (Sigma), 17µM Pantothenate (Sigma), 0.5mM IBMX (Sigma), 10mg/L Transferrin (Sigma), 1µM Rosiglitazone (BioMol), 100nM Dexamethasone (Sigma), 100nM Human Insulin (Recombinant), 2nM triiodo-l-thyronine (T3) (Sigma), reconstituted in ddH₂O to 1liter, pH 7.4. The day cells were first
given Complete Differentiation Media is designated as Day 0. The media was changed every 2 days until the pre-adipocytes were fully differentiated into mature human white adipocytes that were filled with lipid droplets. Following differentiation, the cells were maintained in Maintenance medium until fully differentiated with the media being changed every 2 days. Maintenance medium was made of the similar constituents as Complete Differentiation media, except without Rosiglitazone, IBMX, T3 and Transferrin. Additionally, the concentrations of Human Insulin and Dexamethasone used was 10nm each.

3T3-L1 pre-adipocytes were cultured, differentiated, and maintained as described previously (29). HEK 293T cells were grown in DMEM supplemented with 10% fetal bovine serum in 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.

siRNA Treatment and Adenoviral Transduction of Human Adipocytes - The following siRNA constructs were used for experiments: siScr (from Qiagen) All Stars Negative Control; human siFSP27 (from Dharmacon)-AACUGUACAGACAGAAGAGUA UU. On Day 9 following differentiation, cultured adipocytes were transfected with 40nm siRNA, 5µl/well PLUS reagent and 3µl/well Lipofectamine reagent all from Invitrogen, in a total volume of 350µl/well (100µl siRNA mixture, 250µl MM). 24hrs post-transfection, 500µl Maintenance Media was added to cells. The media was then changed 24hrs later with 1ml of Maintenance Media. Cells were further incubated for 3 days (Day 14) before being harvested for analysis. FSP27-HA tagged adenoviruses were generated at the Adenoviral Vector Core Facility at Tufts Medical Center. FSP-CFP adenovirus was a kind gift from Drs. Carol Szalay and Dawie Gong from the University of Maryland. The adenovirus was added to adipocytes on either Day 9 (if experiment was solely studying effects of over-expression) or on Day 14 (for re-expression analysis) of differentiation at m.o.i of 100. Cells were then harvested 48hrs post-infection for analysis.

RNA Isolation and qPCR - Total RNA was isolated from human adipocytes from each well (12-well plate) with 1ml TRIzol (Invitrogen). Total RNA isolation was performed as described in the manufacturer’s protocol and RNA concentrations were measured on a Nanodrop™ nd-1000 spectrophotometer (Thermo-Scientific). For quantitative PCR (mRNA analysis), 1 µg of RNA was reverse transcribed with Transcriptor First Strand cDNA Synthesis Kit (Roche). The cDNA was diluted 1:10 and 1µl was used for each reaction (per well, 384-well plate) in triplicates. Primers (TaqMan) were used with Roche LightCycler 480 Probes Master kit (Roche Applied Science) at 0.25µl, with 2.5µl Master stock and 1.25µl ddH2O per reaction. Thermal cycling conditions were: 10 min at 95°C for activation, 45 cycles of 10 seconds at 95°C, 30 seconds at 60°C and 1 second at 72°C for reactions, and 5 min at 37°C for cooling down. Comparative-ΔCt method was used to calculate relative changes in mRNA abundance.

Transient Transfections and Reporter Gene Assays - The cDNA for FSP27 was purchased from Open Biosystems; ATGL promoter luciferase constructs (30) and pcDNA3 expression plasmids for Egr1 (31) have been described earlier. Transient transfections with cDNA were performed using Lipofectamine 2000 (Invitrogen Life Technologies, Grand Island, NY) according to the manufacturer’s instructions. Briefly, ca. 80% confluent HEK293T cells were transfected with 1 µg of luciferase reporter constructs, FSP27 cDNA, Egr1 cDNA, and 100 ng of eGFP cDNA in a 6-well plate format.
All experiments were performed in triplicate. After 48 h of transfection, cells were harvested in Reporter Lysis Buffer (Promega). Luciferase activity was determined in whole cell lysates using the Promega luciferase assay kit and expressed as relative light units. Expression of eGFP was measured fluorometrically. Firefly luciferase was normalized by eGFP fluorescence to correct for transfection efficiency.

**siRNA Treatment of HEK293T cells** -
cells in 60 mm dishes were transfected with siScr Smartpool Non-TARGETplus and human siEgr1 Smartpool ON-TARGETplus (Dharmacon Inc, Lafayette, CO) using Lipofectamine 2000 according to manufacturer’s protocol.

**Site-Directed Mutagenesis** -
Nucleotides -44, -42, -41, -40, -36 in the ATGL promoter were replaced for T’s using QuickChange II-XL site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). The primers m1 and m2 for site-directed mutagenesis were synthesized by Eurofins MWG Operon, Huntsville, Alabama. m1: 5’- CAAAATTCTGAGCCAGGCGCCGtGtttTCAtCCGCACTAAAACACCTCCTC-3’; m2: 5’- CTTCGCCTGCTAGCGCCCtGtttTCAtCCGCACTAAAACACCTCCTC-3’ (mutations are shown in small case and underlined). The ATGL promoter constructs 2979/+21 and -48/+21 were used as template for the PCR reaction to produce mutations. The nucleotide sequence of all mutant constructs was confirmed by sequencing.

**Chromatin immunoprecipitation (ChIP) Assay:** ChIP was carried using EZ-Magna ChIP HiSens Kit (Millipore, MA) as described in the manufacturer’s protocol. Briefly, HEK293T cells (75% confluent) were transfected with wild type (wt) and mutated ATGL promoter constructs (-2979/+21), Egr1 cDNA, and Myc-Fsp27 cDNA. Forty eight hours post-transfection, cells were treated with formaldehyde (final concentration 1 %) for 10 min, and then with glycine to quench excess formaldehyde. Cells were collected and suspended in hypotonic nuclei isolation buffer. Nuclei were sonicated using BioRuptor (Diagenode, NJ) with 8 pulses 15 sec each at high setting, and centrifuged for 10 min. Supernatant was immunoprecipitated with 2 µg of the polyclonal antibody against Egr1 (Cell Signaling, MA) or Myc (Millipore, MA) using Magna CHIP protein A/G magnetic beads (10 µl) at 4ºC overnight. Rabbit IgG antibody (Millipore) was used as control. Antibody-bound chromatin fragments were washed three times with low stringency IP wash buffer and eluted from magnetic beads with 50 µl of ChIP elution buffer. Protein-DNA cross-links were treated with proteinase K at 65ºC for 2 h and then at 95ºC for 15 min. DNA was subjected to PCR to amplify the region between -102 and +21 of the ATGL promoter using primers described in (32).

**Immunoprecipitation** - HEK293T cells were co-transfected with Egr1 and HA-tagged FSP27 expression vectors in a 60mm tissue culture dish. Twenty four hour post-transfection, cell lysates were harvested in the lysis buffer (1% Triton X-100, 50 mM Tris, 10 mM EDTA, 150 mM NaCl, protease inhibitor cocktail from Roche). Cell lysates were immunoprecipitated with mouse anti-HA antibody (Roche) or non-specific mouse antibody and anti-mouse Dynabeads overnight at 4ºC on an orbital shaker. Proteins were eluted with Laemmli sample buffer and analyzed by Western blotting.

**Lipolysis Assay** - For analysis of total cellular glycerol and fatty acid release, cells were incubated in Krebs-Ringer buffer (24.6mM NaHCO₃, 1.11mM KH₂PO₄, 130mM NaCl, 4.7mM KCl,
1.24 mM MgSO\(_4\), 3.3 mM CaCl\(_2\), 4% w/v BSA, 5 mM Glucose pH 7.4) for 2.5 hours. Then, buffer was collected and analyzed for glycerol and fatty acid release under basal conditions. Glycerol and fatty acids were measured by using the Serum Triglyceride Determination Kit from Sigma-Aldrich and BioVision Kit respectively according to the manufacturer's instructions.

**Protein Quantification and Analysis** - Cells were lysed in Cell Lysis Buffer (Cell Signaling) with 5% SDS, protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche). Protein lysates were then briefly sonicated, incubated in a 37°C water bath for 30 minutes, and then centrifuged at 10,000 rpm for 10 minutes. The clear middle phase of the solution was then collected as the protein sample. Protein quantification was performed using the Pierce BSA Protein Assay Kit (Thermo Scientific). Immunoblots (Western Blot) were performed using 10% and 15% Tris-HCl gels (Bio-Rad), run at 100 volts for 90 minutes, and transferred to PVDF membranes (Bio-Rad), run at 60 volts, for 120 minutes. Primary antibodies used were all diluted in 2% BSA in TBS-T. Antibodies used were: mouse anti-β-tubulin (Invitrogen, 1:5000 dilution), rabbit anti-FSP27 (1:4000 dilution), and rabbit IgG anti-ATGL (1:5000 dilution). Secondary antibodies were purchased from Santa Cruz Biotechnology (1:10000 dilution).

**Immunostaining and Confocal Microscopy** - Detection of endogenous FSP27 for immunostaining was performed using rabbit FSP27 polyclonal antibody as shown in our recent paper (16). Microscopy was performed using a Zeiss LSM 710-Live Duo scan (Carl Zeiss, Oberkochen, Germany) with a 100X oil immersion objective. Cells cultured on glass cover slips were washed twice with PBS and fixed with 4% paraformaldehyde. Images were processed using Metamorph imaging software, version 6.1 (Universal Imaging, Downingtown, PA).

**Statistics** - Quantitative data are presented as mean ± standard deviation. Statistical significance was calculated using paired student's t-test. A p-value of less than 0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

It has been well established that over-expression of FSP27 suppresses, while ablation of FSP27 increases lipolysis (8,9,12,15-18). Intriguingly, depletion of FSP27 leads to changes in expression of multiple genes, although the mechanism of this effect remains unknown (12,33,34). Given that the rates of lipolysis tightly correlate with the levels of ATGL (35-45), we decided to examine if FSP27 has any role in the regulation of ATGL expression.

Cultured human adipocytes were either treated with siRNA directed against FSP27 or with the scrambled siRNA as control. Cells were harvested 5 days post-transfection, and expression of FSP27 and ATGL was measured by quantitative PCR and Western blotting.

As shown in Fig. 1A & B FSP27-siRNA treatment resulted in 70% knockdown of FSP27 mRNA and 80% knockdown of the FSP27 protein. This decrease in FSP27 expression was accompanied by a 2.8 fold increase in ATGL mRNA, a 1.8 fold increase in ATGL protein, and an increase in basal lipolysis measured by glycerol release (Fig. 1C). Basal FA release was 5-7-fold smaller than glycerol release (Fig. S1A) suggesting high rates of re-esterification in human adipocytes under our experimental conditions (see also (40)).

Next, we treated cultured human adipocytes with adenoviral preparation of CFP-tagged FSP27, or control
adenovirus. As shown in Figs. 1 D & E, even a modest 50% increase in total FSP27 mRNA (endogenous and FSP27-CFP) and protein (not shown) resulted in a decrease in the ATGL protein and a corresponding decrease in basal glycerol release (Fig. 1F; see also Fig. S1B for FA release).

Overall, results shown in Fig. 1 suggest that FSP27 may regulate ATGL expression in human adipocytes at the level of transcription. In order to dissect the mechanism of this regulation, we examined the direct effect of FSP27 on the ATGL promoter activity in HEK293T cells that do not express this protein endogenously. We found that FSP27 inhibited activity of the ATGL promoter in vitro in a dose-dependent fashion (Fig. 2A). Truncation analysis showed that the negative effect of FSP27 on transcription of the reporter gene was maintained even in the case of the shortest ATGL promoter that included only the proximal 48 bp (Fig. 2B). This region of the ATGL promoter contains the binding site for the transcription factor Egr1 (Fig. 2C) that directly binds to and inhibits activity of the ATGL promoter (32). Indeed, upon expression in HEK293T cells, FSP27 and Egr1 demonstrated a synergistic effect in the inhibition of the ATGL promoter activity (Fig. 2D). Knockdown of endogenous Egr1 in HEK293T cells with siRNA (Fig. 2E) attenuated the inhibitory effect of exogenously expressed FSP27 (Fig. 2F). Replacement of 5 nucleotides (underlined in Fig. 2C) in the consensus Egr1 binding site for T's strongly decreased the inhibitory effect of exogenously expressed FSP27 and Egr1 (Fig. 2G). These results suggest that FSP27 inhibits ATGL transcription by potentiating the inhibitory effect of Egr1 on the ATGL promoter.

In agreement with this model, we were able to co-immunoprecipitate Egr1 with HA-tagged FSP27 upon expression of both proteins in HEK293T cells (Figs. 3A) indicating that FSP27 may bind to Egr1. Replacement of HA tag for Myc tag in FSP27 did not affect results of co-immunoprecipitation (Fig. S2).

To get insight into the mechanism of FSP27 action, we carried out chromatin immunoprecipitation assay using HEK293T cells transfected with Egr1 and myc-tagged FSP27 in different combinations. In these experiments, we used full size (-2979/+21) wild type and mutated ATGL promoters, and we amplified 200 bp long region that included the proximal Egr1-binding site shown in Fig. 2C. As expected, Egr1 interacted with its own binding site, and mutation of this site blocked binding (Fig. 3B) which is consistent with results shown in Fig. 2G. Interestingly, co-transfection of Egr1 together with myc-FSP27 significantly increased binding of Egr1 to the wild type ATGL promoter (Fig. 3B).

Note, that exogenously expressed myc-FSP27 was also associated with the wild type but not mutated Egr1-binding site of the ATGL promoter (Fig. 3B). To determine whether this interaction is mediated by the endogenously expressed Egr1, we carried out ChIP experiments using Egr1 KD cells (Fig. 2E). We found that in the absence of Egr1, the interaction of FSP27 with the ATGL promoter is abrogated (Fig. 3C) suggesting that FSP27 interacts with DNA not directly, but via Egr1.

Previous studies have established that most of FSP27 in adipocytes is associated with LDs (8-10), although some of this protein has also been detected in other intracellular compartments (16) and in particular, in the cell nucleus (46). Indeed, our subsequent analysis showed that a significant fraction of FSP27 is localized in the nucleus of human adipocytes (Fig. 3D). Thus, we conclude that FSP27 inhibits lipolysis, at least in part, by potentiating the effect of Egr1 on ATGL transcription. As expression of both Egr1 (32) and FSP27 (47) is strongly
up-regulated by insulin, this regulatory axis may contribute to the anti-lipolytic effect of insulin which is essential for normal lipid partitioning and overall metabolic health (26).

The functional connection between FSP27, Egr1, and lipolysis described in this report may represent a regulatory loop that couples the size of lipid stores in the adipocyte to transcription in the nucleus. Indeed, in obesity, fat tissue mass can expand by an order of magnitude and more. A proportional increase in lipolysis and circulating FA would be life threatening. Fortunately, fasting plasma FA levels demonstrate a much more modest increase and are largely unrelated to body fat mass (48), although the mechanisms of this compensation are not known. One such mechanism may be the suppression of ATGL expression (32,49) by Egr1 and FSP27 that are both up-regulated by high-fat feeding (32,50). This may represent a compensatory response in adipocytes that keeps circulating FAs within physiological range and protects the body from detrimental effects of obesity.

Our observations may mechanistically explain many of the previously described physiological functions of FSP27. Thus, FSP27-deficient mice are protected from diet-induced obesity and insulin resistance (11,12,51) – the phenotype which is mimicked by adipose-specific over-expression of ATGL (52). Furthermore, the link between FSP27 knock out, fat catabolism, and mitochondrial oxidation (11) may also be mediated by ATGL that up-regulates mitochondrial activity by producing a yet unidentified ligand for PPARα (53).

Finally, we would like to point out that while our experiments were in progress, Wang et al. reported that FSP27 interacts with and co-activates C/EBPβ (54). Thus, FSP27 may emerge as a novel regulator of adipocyte transcription.

ACKNOWLEDGEMENTS

We would like to thank Drs. Susan Fried and Valentina Perissi (Boston University Medical School) for helpful and insightful discussions. This work was supported by research grants DK52057 and AG039612 from the NIH, research grant 7-11-BS-76 from the American Diabetes Association and research award from the Allen Foundation to K.V.K., NIH grants R56DK094815, 8KL2TR000158 (from the parent grant UL1-TR000157 to Clinical and Translational Science Institute, Boston University), and Boston Nutrition and Obesity Research Center pilot grant P30DK046200 to VP.
REFERENCES


Figure 1. FSP27 negatively regulates ATGL expression and lipolysis in human adipocytes. Human adipocytes were cultured and differentiated as described in Experimental Procedures. Panel A: RNA was extracted from control and siRNA-treated adipocytes, and mRNA levels were measured by quantitative PCR and normalized by GAPDH mRNA. The data show an average of three independent experiments. Panel B: Protein lysates from control and siRNA-treated adipocytes were loaded at 15 µg/lane and probed with antibodies against FSP27, ATGL or β-tubulin. Image is representative of at least three independent experiments. Panel C: FSP27 knockdown increases basal lipolytic rate measured during 2.5 h incubation in KRB with 4% BSA in human adipocytes. Panel D: RNA was extracted from adipocytes treated with adenovirus expressing FSP27-CFP or control adenovirus, and mRNA levels were measured by quantitative PCR and normalized by GAPDH mRNA. The data show an average of three independent experiments. Panel E: protein lysates from adipocytes treated with adenovirus expressing FSP27-CFP or control adenovirus were loaded at 15 µg/lane and probed with antibodies against ATGL and β-tubulin. Image is representative of experiment performed in triplicates. Panel F: FSP27-CFP expression decreases basal lipolytic rate measured during 2.5 h incubation in KRB with 4% BSA in human adipocytes. All values are means ± SD; * p < 0.05 as estimated by unpaired t-test.

Figure 2. FSP27 inhibits ATGL promoter activity via Egr1. Panels A, B, D, F, and G: HEK293T cells cultured in 12-well dishes were transfected with the full length (-2979/+21), C→T mutated, or truncated ATGL luciferase promoter constructs, cDNA for eGFP; cDNAs for Fsp27 and Egr1 as well as scrambled siRNA and Egr1 siRNA as indicated. After 48 h, cells were washed three times in cold PBS and harvested in the reporter lysis buffer. Luciferase activity in cell lysates was assayed and normalized by eGFP fluorescence. Data are presented for triplicate samples as mean±SD; * p < 0.05 as estimated by unpaired t-test. In panel D, # indicates the synergistic effect between Egr1 and FSP27 with p < 0.05. Experiments were repeated at least 3 times (panels A, B, D, G) and 2 times (panel F). Panel C: Schematic representation of the proximal region of ATGL promoter with the consensus Egr1 binding site. Nucleotides that have been chosen for the site-directed mutagenesis are underlined. Panel E:
HEK293T cells growing in 35 mm dishes were transfected with scrambled or Egr1 siRNA. Cell lysates were collected 48 h post-transfection, separated by 12.5% PAGE and immunoblotted with Egr1 and actin antibodies. Experiment was repeated at least 2 times.

**Figure 3.** FSP27 interacts with Egr1 and facilitates its recruitment to the ATGL promoter. Panel A: HEK293T cells were co-transfected with Egr1 (2 µg) and HA-tagged FSP27 (4 µg) expression vectors in a 60 mm tissue culture dish. Twenty four hour post-transfection, cell lysates (500 µg) were immunoprecipitated with mouse anti-HA antibody (1 µg) or non-specific mouse antibody and anti-mouse Dynabeads overnight at 4°C on an orbital shaker. Proteins were eluted with Laemmli sample buffer and analyzed by Western blotting. Experiment was repeated at least 3 times. Panel B: ChIP assays were performed in HEK293T cells transfected with either wild type (WT) or mutated ATGL promoter (0.5 µg), Egr1 and Myc-Fsp27 cDNAs (2 µg each). Isolated chromatin was immunoprecipitated using polyclonal antibodies against Egr1, Myc or non-specific rabbit IgG; PCR amplified cDNA fragments were separated in 2% agarose gel and visualized using ethidium bromide. Experiment was repeated 3 times. Panel C: ChIP assay was performed in HEK293T cells transfected with the wild type ATGL promoter (0.5 µg), scrambled siRNA and Egr1 siRNA. Experiment was repeated 2 times. Panel D: Endogenous FSP27 (green) was visualized in cultured human adipocytes by immunofluorescence as described in Experimental Procedures with (left) or without (right) DAPI nuclear staining. Experiment was repeated at least 3 times.
Figure 1
Figure 2
Figure 3
Fat specific protein 27 inhibits lipolysis by facilitating the inhibitory effect of Egr1 on transcription of adipose triglyceride lipase
Maneet Singh, Rajween Kaur, Mi Jeong Lee, R. Taylor Pickering, Vishva Mitra Sharma, Vishwajeet Puri and Konstantin V. Kandror

J. Biol. Chem. published online April 17, 2014

Access the most updated version of this article at doi: 10.1074/jbc.C114.563080

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2014/04/17/C114.563080.DC1

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2014/04/17/jbc.C114.563080.full.html#ref-list-1